Saturday, September 26, 2026
BTC $84,103 ▲ 0.01%
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
LIVE
ADA$0.256down−0.87%ETH$2,687down−0.15%LINK$14.08up+1.07%SOL$120.38down−1.42%BTC$84,103up+0.01%XRP$1.55down−1.38%S&P 5007,743up+0.51%Nasdaq27,069up+0.48%Dow51,829up+0.93%RUT2,838up+0.07%TNX5.18%up+0.43%TYX5.50%up+0.79%FVX5.01%down−0.36%IRX4.07%up+0.05%VIX14.87down−5.11%GOLD$4,321.20up+0.54%SILVER$64.80up+1.25%OIL$92.41down−2.33%DXY101.03up+0.06%NVDA$225.07up+0.22%AAPL$341.07up+1.53%TSLA$372.11down−1.54%META$751.66down−3.33%MSFT$516.17up+3.66%AMZN$249.67up+0.12%GOOGL$343.92up+0.46%Fear & Greed74 — GreedADA$0.256down−0.87%ETH$2,687down−0.15%LINK$14.08up+1.07%SOL$120.38down−1.42%BTC$84,103up+0.01%XRP$1.55down−1.38%S&P 5007,743up+0.51%Nasdaq27,069up+0.48%Dow51,829up+0.93%RUT2,838up+0.07%TNX5.18%up+0.43%TYX5.50%up+0.79%FVX5.01%down−0.36%IRX4.07%up+0.05%VIX14.87down−5.11%GOLD$4,321.20up+0.54%SILVER$64.80up+1.25%OIL$92.41down−2.33%DXY101.03up+0.06%NVDA$225.07up+0.22%AAPL$341.07up+1.53%TSLA$372.11down−1.54%META$751.66down−3.33%MSFT$516.17up+3.66%AMZN$249.67up+0.12%GOOGL$343.92up+0.46%Fear & Greed74 — Greed
Tag

argenx

1 article

Argenx's Vyvgart Franchise Offers 23% Upside; Four Studies Coming
U.S. Equities1h ago
Argenx's Vyvgart Franchise Offers 23% Upside; Four Studies Coming
The biotech reported 60% year-over-year revenue growth in Q2 2026 on gMG and CIDP therapies, with Wall Street's consensus target at $1,180.25.